initi coverag loxo oncolog overweight pt
short period loxo becom leader precis medicin field
reflect compani effici approach drug discoveri develop
believ treatment effect demonstr larotrectinib clinic trial obviou
impress appropri patient perfect proof concept
compani also believ bayer collabor bayn cover make lot
sens given patient identif effort requir promis rest
pipelin hold addit high expect believ
repres excit approach opportun current reflect
share price overweight base potenti compani trk fusion
ret alter franchis addit valu creation possibl
abstract impress respons seen
patient broken tumor type respons rate
nsclc mtc respons unaffect
prior mki treatment naiv vs treat rate across indic
higher recent observ competitor blueprint uncov
mki-treat patient respond believ put
loxo firmli lead
data even better confer note abstract
januari data cut upcom oral present april data
cut manag recent note data confer improv includ
patient also focu safeti profil could provid
differenti appear caus hypertens
larotrectinib convinc initi proof concept laro shown induc
tumor-agnost respons patient posit trk fusion patient
acquir resist demonstr abil salvag respons
extend durat therapi believ laro like receiv fda approv
fall trk franchis potenti gener global sale
loxo prime takeout candid given data gener
program believ promis loxo approach drug develop
clear signific player oncolog would benefit compani
drug discoveri platform scenario takeout oper expens
meaning reduc believ loxo share could worth well
still attribut valu revers btk program
commerci risk laro develop risk
loxo leader purpose-built medicin oncolog
dcf includ profit
royalti global
bayer collabor world-wide sale
includ
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tabl content
demonstr efficaci initi readout provid benchmark loxo-
page
page
loxo oncolog biopharmaceut compani whose mission develop innov life-
save therapi patient genetically-target cancer sinc loxo built
tissue-agnost biologically-driven pipelin boast highly-select target therapi
specif mutat pan-canc indic approach increas rel
probabl success clinic develop molecule/target discov
leverag key insight clinic data loxo pipelin exploit oncogene-addict
therapeut design target tumor molecular depend order induc
cancer cell death collabor array biopharma arri cover ted tenthoff
compani gener pipelin candid clinically-valid target high select
effect loxo develop truli person therapi potenti provid single-
agent robust tumor control limit off-target side effect latter
histor jeopard success therapi
advanc trk inhibitor franchis forward loxo recent enter global
develop commerci partnership bayer bayn cover believ
relationship provid necessari resourc develop commerci
provid loxo near-term cash potenti
addit mileston half manag believ attain
lead candid larotrectinib trk inhibitor partner bayer
target tumor trk fusion-posit mutat
next-gener revers trk inhibitor partner bayer
design second-lin trk inhibitor patient develop trk inhibitor
ret inhibitor wholly-own design treat cancer pan-
ret mutat
next-gener btk inhibitor wholly-own aim provid
diseas control grow number btk inhibitor-tr patient develop
note loxo commerci success larg depend develop companion
diagnost identifi appropri patient importantli fda taken leadership
posit promot develop genetically-defin tissue-agnost therapi
evidenc keytruda approv use tissue-agnost cancer fda-sponsor
workshop host therapi may assist identif patient loxo
partner roch ventana cover develop ihc-bas diagnost assay
specif trk franchis compani also enter agreement
cover quirk optim next-gener sequencing- base assay
detect mutat therapi across loxo develop portfolio
page
moment invest thesi larg focus clinic success larotrectinib
believ pipelin candid import long-term valu constitu
resist mutat kinas inhibitor treatment set continu meaning increas
view import near-term mileston compani
updat data studi present american societi
clinic oncolog meet june
new patient data updat durabl data cohort larotrectinib studi
also present
initi proof-of-concept data studi expect second half
submiss larotrectinib expect sometim
page
cancersglob bayer partnershippdufaunresectable/metastat solid tumor ntrk-fusion submiss emaunresectable/metastat solid tumor ntrk-fusion bayer trk program phase ii studi updateunresectable/metastat solid tumor ntrk-fusion bayer partnershiptrk inhibitor-resist program phase i/ii studi updatedevelop resist trk mutat cancerswholly-ownedret program phase studi updatecanc ret fusion ret submissiondevelop resist btk inhibitor therapi cell btk resist program phase studi develop resist btk inhibitor therapi cell genet screen
broad adopt test cancer mutat essenti mani patient access
best therapeut option infrastructur current lack howev need truli
exist nci match trial offer free ngf test commun site program
quickli deplet fund even biomark interest could offer
believ though signific progress made clinic regulatori payor
standpoint toward increas access patient
futur person cancer therapi rest adopt reimburs
diagnost panel current test ubiquit potenti patient benefit
genetically-defin treatment may miss time community-bas center
test patient access test like increas lab reimburs continu
improv note thermofish cover oncomin foundat medicin fmi
cover foundationon companion diagnost cdx assay approv
fda avail clia-certifi laboratori cdx like increasingli focu
approach due abil multiplex kit mani ten hundr
assay exampl illumina trusight tumor genotyp panel cover
gene associ solid tumor singl assay allow cost-effect effici
comprehens detect subsequ diagnosi across mani potenti mutat patient
cancer may display potenti result identif action target
specif loxo manag exceedingli transpar market uptak initi
slow due lack widely-avail genet test due need develop
broad genet test identifi rel small number patient howev believ
advanc ihc- ngs-base detect method includ trk ret
mutat along improv regulatori reimburs climat enabl clinic
success pipelin product abl reach correct patient
discuss previous loxo proactiv enter partnership roch ventana
develop ihc- ngs-base companion diagnost respect pipelin
product near-term roch partnership intend improv approach toward
ntrk fusion current method yield false-posit ngs-base mutat detect
challeng ntrk gene contain larg intron creat reliabl issu
develop diagnost pan-trk assay sold ran clia-certifi lab howev
futur like give way test multiplex
favor payor perspect thu long-term collabor work
toward obtain regulatori approv ngs-base multi-gen panel tumor profil
panel expans trusight tumor test intend futur
companion diagnost loxo trk ret franchis overal pivot partnership
loxo product test avail today dialed-in trk fusion coverag
note diagnost partnership like loxo appear recent trend precis
medicin oncolog space bristol-my squibb cover among other
recent partner develop variou assay believ continu develop
improv diagnost parallel increas avail person therapi
along payor traction continu chang way oncologist categor
page
recent year research clinic data reveal mani cancer matter organ
origin share common patholog gene signatur interestingli analysi signatur
indic larg major tumor tend depend singl genet alter
signal cascad phenomena known oncogen addict therebi provid ration
interven target person cancer therapi potenti special oncolog
therapeut base patient tumor type diagnos directli treat
genet caus tumor believ effort like enhanc chanc clinic
benefit histor difficult-to-treat cancer subtyp
loxo believ understand oncogen addict yield novel efficaci cancer
therapi target key genet cogs tumor small molecul inhibitor tumor
prolifer surviv greatli impair loxo analyz histor clinic data found
treatment respons discrep genet subset patient correl poorer
outcom appli knowledg drug develop program
larotrectinib compani most-advanc clinic program origin
identifi seri high-throughput screen partner array biopharma oral
highly-select potent inhibitor tropomyosin receptor kinas trk develop
treatment cancer trk fusion trk fusion mutat ntrka
gene caus chronic activ oncogen map-kinas pathway
implic mani cancer sarcoma loxo believ target inhibit
trk pathway may provid clinic benefit genetically-defin patient whose tumor driven
trk loxo note moonshot fact nsclc patient mutat egfr
achiev much higher respons rate erlotinib vs unselect patient
basi first-lin label indic addit xalkori alk nsclc
zelboraf braf melanoma gleevec ph chronic myeloid leukemia
success develop oncogen driver signific clinic benefit patient
discuss later report larotrectinib also gener compel clinic data
novemb loxo enter partnership bayer trk inhibitor franchis
larotrectinib discuss next section loxo lead global
develop activ cost equal share two compani split
regulatori respons loxo nda accept grant prioriti
review pdufa date set novemb bayer ex-u submiss
expect sometim two compani co-promot product
cost equally-shar profit split bayer commerci ex-u pay tier
double-digit royalti net sale importantli deal enhanc resourc know-
need commerci product environ access test
current limit exampl bayer commerci radio enhanc product xofigo acquir
algeta purchas prostat cancer
meet pivot event loxo larotrectinib compani
present initi data trk fusion-posit cohort compani demonstr
larotrectinib effect safe importantli loxo shed light drugabl trk
fusion-posit tumor oncologist accord manag larg unawar
genotyp good first step increas awar larotrectinib
page
clinic program larotrectinib encompass three trial includ patient across
pivot dataset publish nejm earlier year public detail result
trk fusion-posit patient pool three cohort overal respons rate orr
determin independ review committe investig origin
report figur exhibit manag note minim discrep
two investig bodi speak therapeut efficaci larotrectinib major
differ endpoint interpret rais concern worth note report data includ
patient whose trk fusion statu fals posit lower final orr
page
page
indicationtri nameadult phase iscoutnavigateaverag phase iphas i/iiphas ii basketlatest sourceaacr fusion-posit performance-statu previou system mutationtrka datamedian time respons respons central respons rate analysi treatment cur respons resist averag column contain dose-escal patient scout trial fusion-posit cancer respons
recent data cutoff juli current median respons time month
patient respond larotrectinib continu treatment
undergon cur surgeri loxo note larotrectinib therapi may facilit surgeri
previous unresect sarcoma month follow-up subset patient
exhibit on-going respons progression-fre exhibit median
progression-fre surviv current met model predict achiev within
month find compar favor genetically-defin therapi like
alectinib alk metastat nsclc whose month also worth note even
patient progress may remain treatment continu slow progress
importantli respons larotrectinib independ age tumor type ntrk mutat
fusion partner exhibit give us confid therapeut approach
manag hope result serv motiv encourag access comprehens
genom profil applic person cancer therapi
page
safeti profil larotrectinib exceedingli favor advers event
predominantli grade treatment-rel advers event grade note
occurr patient treatment-rel discontinu record
note critic maintain respons patient requir dose reduct
origin continu bid dose importantli best respons maintain
loxo continu enrol addit trk fusion-posit patient origin cohort
expect new patient durabl data patient present
june given momentum gener nejm public
like thesis-alt optimist data updat continu
demonstr robust respons strong durabl
page
clinic trial data highlight phenomenon known acquir resist use tumor
evad death often mutat limit drug bind render current therapeut
option ineffect evidenc diseas progress despit oncogene-addict
tumor tend remain addict oncogen necessit develop
secondari treatment need select efficaci initi therapi
overcom resist mutat induc tumor death develop next-gener
therapeut address acquir resist provid signific clinic valu patient
new therapi potenti re-engag tumor respons provid extend
loxo aim develop next-gener inhibitor re-induc respons patient
acquir resist mutat partnership array biopharma loxo develop
next-gener select trk inhibitor design overcom acquir resist patient
stop respond prior trk inhibitor treatment includ larotrectinib roch
entrectinib other case acquir resist defin diseas progress
occur treatment least period respons stabl diseas
acquir resist seen patient
 origin respond
larotrectinib trial genet analysi
patient develop acquir resist
reveal case solvent front mutat
case gate keeper mutat case
xdfg mutat loxo note one
patient incur two mutat exampl
mutat identifi present
resist due physic hindranc
find relev object
aim accommod mani
class mutat order re-engag
tumor trk inhibitor therapi interestingli
mutat document occur
class kinas inhibitor
believ may allow pipelin expans
loxo transfer two patient previous discuss larotrectinib studi develop
acquir resist onto first-in-human basi patient close monitor
rapid dose titrat remark therapi led rapid tumor respons therebi
demonstr abil re-induc tumor respons extend diseas control durat
believ result provid initi valid develop program
efficaci evalu phase i/ii trial trial co-loc high-
enrol larotrectinib trk fusion-posit patient trial site key enrol
requir histori diseas progress prior trk inhibitor look forward
initi efficaci read second half
page
loxo estim incid trk fusion cancer around per year
us given trk fusion occur wide rang solid tumor genom test
wide avail yet believ small percentag patient current
identifi said loxo partner bayer prepar larotrectinib launch
heavi focu diagnost patholog lab commun estim
third patient identifi patient identifi
assum vast major treat laro follow launch next year
initi durat respons month increas time avail
assum price laro monthli basi
compar current approv kinas inhibitor result us sale
ex-u loxo believ similar number patient europ japan
model first ex-u launch year later bayer gener sale
page
fiscal year end statesincid trk fusion cancer trk fusion patient identifi trk fusion larotrectinib patient identifi trk fusion launchmean durat respons patient annual price per patient us sale ww stateslaro ex-u sale ww ww sale ret mutat
mutat rearrang transfect ret transmembran tyrosin kinas
implic numer tumor type similar trk fusion-posit mutat aberr gain-of-
function mutat ret lead chronic stimul oncogen pathway fuel cancer cell
ret mutat includ extracellular mutat intracellular mutat account
medullari thyroid cancer mtc oncogen fusion
account nsclc papillari thyroid cancer exhibit loxo estim
amount late-stag elig cancer patient per year patient
tend identifi easili oncogen mutat trk fusion-posit
mutat discuss previous ret fusion/mut diagnost assay alreadi
establish test mandat nation comprehens cancer network guidelin
nsclc specif mtc test common gatekeep mutat affect
atp-bind pocket ret confer resist kinas inhibitor current test
gatekeep mutat identifi kinas inhibitor target includ egfr
bcr-abl render treatment ineffect nonetheless find patient critic
despit ret mutation-posit cancer repres action target current ret inhibitor
larg un-optim number off-target effect exist multi-tyrosin kinas
inhibitor mki repurpos ret inhibitor cabozantinib vandetanib lenvatinib
alectinib poor ret target inhibit respect human
like result poor pharmacokinet mki provid minim efficaci
nsclc orr mtc orr patient exhibit therefor signific
opportun exist develop inhibitor specif ret demonstr better
select target engag effect multipl type ret mutat
addit patient administ mki ret develop acquir resist
develop compound predict activ resist mutat
ideal order increas durat respons patient
page
loxo believ specif target ret potenti provid better outcom ret-
posit patient cite increas overal surviv os observ exam phase trial
studi cabozantinib ret-posit mtc exampl orr median os
month vs month placebo end develop potent
highly-select ret inhibitor includ pan-ret fusion mutat importantli
bind inhibit trigger dose-limit toxic includ qtc
prolong hypertens common issu current mki exhibit toxic
signific caus frequent dose reduct and/or interrupt may caus
patient progress
current mki use ret-posit patient ineffect exhibit signific
sever preclin model shown reduc tumor growth enhanc surviv
rate ret lung cancer model exhibit note activ model acquir
resist gatekeep mutat current mki optim
page
loxo initi phase trial studi singl agent patient ret-fus nsclc
histori prior mki treatment regardless brain metastasi statu exhibit
page
intern associ studi lung cancer iaslc meet septemb
patient enrol dose level first patient dose may
loxo observ dose-limit toxic like result reduc off-target
effect inhibit dose-escal pk studi display proport
relationship dose suggest specif ret target engag compani also
note provid better ret coverag measur inhibit compar current
mki respect inhibit rate describ
septemb data cutoff demonstr proof concept anti-
tumor efficaci two mki-resist ret-fus nsclc patient one mtc patient
gatekeep mutat specif case describ detail patient
fusion progress mki treatment exhibit partial respons remain
treatment month patient fusion brain metastas previou
mki histori exhibit system partial respons case
particularli relev patient brain metastas penetr brain
critic treat patient patient ret along
acquir ret gatekeep resist mutat demonstr robust decreas
tumor biomark confirm tumor respons remain treatment
dose-escal phase trial on-going patient continu enrol
manag note enrol go well pace meet studi aim next data
updat take place june loxo note cohort includ patient
extens mki treatment histori sever ret mutat thu expect data
interpret respect ret mutat across board
abstract submit saw preview share oral
present orr evalu patient exhibit orr
unaffect prior mki treatment orr mki-nav vs mki-treat nsclc
orr orr mtc orr
includ pr one mtc patient display pr gatekeep
mutat prior treatment mki also mtc patient
decreas serum calcitonin week major patient remain
treatment durat respons reach longest respons greater
month importantli seriou treatment-rel discontinu record
page
loxo primari competitor space raymond
design anoth potent select ret inhibitor past april blueprint
present initi clinic data may slight edg kinom specif
exhibit ret select compar fold vs fold
page
iarrow phase iphas iarrow phase iphas iarrow phase iphas iarrow phase icompanyloxoblueprintloxoblueprintloxoblueprintloxoblueprintlatest sourceasco performance-statu previou system enrol patient enrol patient enrol patient line datamedian durat respons rate nsclcret-mut mtcret-fus exhibit
benchmark loxo-
piper jaffray adapt loxo oncolog
data blueprint present clinic proof-of-concept data on-going phase
arrow studi provid evid induc durabl clinic respons
patient ret-alt nsclc mtc exhibit treatment led orr ret-
fusion nsclc orr ret-mut mtc separ
 mki-nav patient respond rate decreas
patient prior mki treatment histori blueprint associ discrep due patient
note potenti demonstr better orr time current
data indic drug dose-depend effect inhibit ret pathway tumor
biomark enrol patient patient tumor shrinkag yet meet
pr cutoff reduct could convert sd pr later date patient
place higher dose interest see orr mtc increas
time ret-alt mtc constitut major address patient product
current orr similar achiev cabozantinib albeit reduc
toxic patient maximally-toler dose
need wait addit data updat trial loxo data
updat accur compar clinic profil appear may
greater efficaci overal patient prior mki treatment histori discuss
data suggest patient respond less favor mki-nav
patient continu demonstr better efficaci subset patient believ
could differenti
term safeti report rel well-toler patient
exhibit grade treatment-rel exhibit note appear concern
hypertens present oncologist note case
easili manag littl clinic signific ascrib concern due hypertens
well-docu side effect mki use believ off-target inhibit
respons
page
accord safeti data describ abstract find clearli safer
grade advers event treatment-rel discontinu record also
import note hypertens describ believ posit safeti
profil could due higher select ret specif kinom plot
compar
similar situat laro howev key differ ret
alter occur smaller number solid tumor rel trk fusion primarili lung
thyroid cancer patient identif ultim commerci effici
assum half patient ret alter
year identifi estim launch could
conserv given posit recent data abstract present
confer earli june assum treat identifi
ret alter patient similar price around per month
result us sale similar number patient ex-u believ ex-u
sale could approach result combin global opportun well
page
iarrow phase icompanyloxoblueprintlatest sourceasco blood cell lead tx discontinu cancer exhibit
page
fiscal year end statesincid lung thyroid ret cancer ret alter patient identifi ret alter launchnew patient identifi ret alter durat respons patient annual price per patient us sale ww ex-u ww ww new subset
irrevers coval bruton tyrosin kinas inhibitor btki transform treatment
 cell malign includ chronic lymphocyt leukemia cll mantl cell lymphoma
mcl waldenstrom macroglobulinemia wm margin zone lymphoma mzl amongst
other present ten thousand patient undergo chronic therapi sign
resist emerg result diseas progress similar mki-rel resist
describ previou section clinic evid first report suggest
patient develop resist mutat becom unrespons coval btki therapi
like ibrutinib acalanitib like other well
resist creat mutat coval btki bind site locat
coval btki bind loxo believ may respons diseas
progress case though exact rate patient develop resist mutat
known address popul expect increas patient go coval btki
therapi longer period time creat unmet need increas clinic
signific time believ could eventu result signific market
juli loxo purchas redx pharma btki program gave right
lead candid renam loxo subject mileston royalti
payment redx pharma next-gener revers btki potenti
overcom resist acquir coval btki much like candid
compani pipelin exhibit attract drug properti design highly-select
minim advers event non-coval bind btk site independ
posit compani believ treatment may re-induc respons therapi
restor diseas control loxo note revers inhibitor new approach
current tki revers howev challeng obtain sustain coverag
believ achiev
current loxo complet pre-ind work ind submiss clinic trial initi
plan take place second half year note loxo seek enrich
phase cohort patient relaps prior btki therapi moreov revers btki
potenti overcom resist acquir coval btki test
mutat yet routin loxo manag note rel straightforward
util either blood bone marrow lymph node tissu long-term manag
intend compet biolog challeng first-lin therapi serv
address increas rate coval btk intoler
page
revenu build compos futur profit bayer us collabor
royalti bayer ex-u sale world-wide sale revenu
bayer up-front anticip mileston
model us laro launch next year reach market
coupl year later ad durat treatment patient trk fusion cancer
expect franchis durabl late laro patent start
expir model gross margin approach time profit
margin approach high us sale expect would result
nearli profit loxo
ex-u anticip laro launch partner bayer follow coupl year
later lead eventu sale assum tier double-digit royalti
result nearli loxo
model us launch loxo eu launch occur year
later estim global sale approach franchis
remain durabl late patent famili expir
given larger global opportun rel econom better durabl
repres largest compon valuat
collabor revenu per manag guidanc model
respect result remain bayer up-front futur expect
page
fiscal year end product revenu mm laro bayer us collabor margin gener administr /profit global product bayer ex-u collabor earn global product us launch eu launch year world-wide global product global product total collabor agreement revenu loxo bayer up-front anticip mileston
gross margin approach low small molecul
compani captur bayer collabor profit royalti taper
three product launch respect indic sg ramp industri
norm global launch note cog sg expens
alreadi includ cost/profit share calcul revenu build
current configur loxo achiev oper profit time-frame
anticip oper margin approach impress final
assum standard long-term tax rate around
addit assumpt add back stock compens includ futur
expect array mileston get long-term ebit margin high
cash debt discount futur cash flow back interest rate
larg assum success launch laro arriv dcf-
base valuat per share loxo basi price target note
success develop target larg grow btk treatment
market estim approach early-to-mid current reflect
dcf could inflect valuat
page
fiscal year end product revenu mm laro bayer us collabor /profit global product bayer ex-u collabor global product world-wide global product global product collabor agreement revenu loxo good develop revenu gener revenu expens revenu incom incom loss interest incom non-oper loss revenu incom loss earn per outstand remain bayer up-front anticip mileston exhibit
believ loxo prime takeout candid follow posit result
expect scenario assum potenti biotech pharma
compani establish oncolog commerci infrastructur abl remov
major anticip expens halv expect sg spend result
potenti dcf-base takeout valuat per share exhibit
page
assumpt output mm tyler van buren share outstand share biotech analyst increas work capit year end loxo good develop revenu gener revenu expens revenu stock incom tax oper profit work capit valueloxo discount valuationpiperjaffray exhibit
risk associ loxo oncolog common biotech compani describ
detail
clinic risk success clinic trial essenti loxo partner market
product success clinic guarante invest thesi overweight rate
larg assum success develop larotrectinib
regulatori risk fda regulatori bodi may differ view benefit-risk
balanc demonstr clinic test compani seek approv loxo may
requir addit trial may make develop candid time
cost- prohibit assum success regulatori review larotrectinib
commerci risk oncolog space larotrectinib oper specif
challeng multipl competitor signific price pressur addit
larotrectinib success develop enter market companion diagnost
streamlin may make difficult locat patient appropri larotrectinib
also face competit similar product could come onto market
time clinic and/or regulatori success guarante commerci success
financ risk loxo pipelin develop commerci plan requir capit time
addit fund partner loxo may need rais money equiti
offer may neg impact stock price
page
assumpt output mm tyler van buren share outstand share biotech analyst increas work capit year end loxo good major expens halv sg develop revenu gener revenu expens revenu stock incom tax oper profit work capit discount valuationtermin valuepiperjaffray
intellectu properti risk protect loxo drug process depend issu
pend patent in-hous knowledg one parti often challeng intellectu
properti estat success product claim prioriti patent patent
invalid infring signific expens legal protect could requir futur
guarante success patent expiri includ laro
page
unresectable/metastat solid tumor ntrk-fusion protein
unresectable/metastat solid tumor ntrk-fusion protein
unresectable/metastat solid tumor ntrk-fusion protein
data addit patient durabl data initi later data cut juli nejm public data regulatori discuss
develop resist trk inhibitor
dose first patient may
cancer ret fusion ret mutat
resist intoler
develop resist btk inhibitor therapi cell malign
develop resist btk inhibitor therapi cell malign
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
global product revenu
global product revenu
global product revenu
good sold
revenu
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
